Diabetes Care, Vol 20, Issue 5 725-734, Copyright © 1997 by American Diabetes Association

ARTICLES

Model of complications of NIDDM. I. Model construction and assumptions

RC Eastman, JC Javitt, WH Herman, EJ Dasbach, AS Zbrozek, F Dong, D Manninen, SA Garfield, C Copley-Merriman, W Maier, JF Eastman, J Kotsanos, CC Cowie and M Harris
Division of Diabetes, Endocrinology, and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892-2560, USA.

OBJECTIVE: To develop a model of NIDDM for analyzing prevention strategies for NIDDM. RESEARCH DESIGN AND METHODS: A Markov type model with Monte Carlo techniques was used. Age, sex, and ethnicity of cohort was based on U.S. data. Incidence rates of complications were also based on community and population studies. RESULTS: Nonproliferative retinopathy, proliferative retinopathy, and macular edema are predicted in 79, 19, and 52%, respectively, of people with NIDDM; 19% are predicted to develop legal blindness. Microalbuminuria, gross proteinuria, and end-stage renal disease related to diabetes are predicted in 53, 40, and 17%, respectively. Symptomatic sensorimotor neuropathy and lower-extremity amputation are predicted in 31 and 17%, respectively. Cardiovascular disease is predicted in 39%. Higher rates of complications (1.1-3.0x) are predicted in minority populations. Predicted average life expectancy is 17 years after diagnosis. CONCLUSIONS: A probabilistic model of NIDDM predicts the vascular complications of NIDDM in a cohort representative of the incident cases of diabetes in the U.S. before age 75 years. Predictions of complications and mortality are consistent with the known epidemiology of NIDDM. The model is suitable for evaluating the effect of preventive interventions on the natural history of NIDDM.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E. S. Huang, Q. Zhang, N. Gandra, M. H. Chin, and D. O. Meltzer The Effect of Comorbid Illness and Functional Status on the Expected Benefits of Intensive Glucose Control in Older Patients with Type 2 Diabetes: A Decision Analysis Ann Intern Med, July 1, 2008; 149(1): 11 - 19. [Abstract] [Full Text] [PDF]

				L. Monnier and C. Colette Glycemic Variability: Should we and can we prevent it? Diabetes Care, February 1, 2008; 31(Supplement_2): S150 - S154. [Abstract] [Full Text] [PDF]

				S. Colagiuri and A. E. Walker Using An Economic Model Of Diabetes To Evaluate Prevention And Care Strategies In Australia Health Aff., January 1, 2008; 27(1): 256 - 268. [Abstract] [Full Text] [PDF]

				A. J. Sinclair Special Considerations in Older Adults With Diabetes: Meeting the Challenge Diabetes Spectr, October 1, 2006; 19(4): 229 - 233. [Abstract] [Full Text] [PDF]

				E. J. Dasbach, E. H. Elbasha, and R. P. Insinga Mathematical Models for Predicting the Epidemiologic and Economic Impact of Vaccination against Human Papillomavirus Infection and Disease Epidemiol. Rev., August 1, 2006; 28(1): 88 - 100. [Abstract] [Full Text] [PDF]

				L. Monnier, E. Mas, C. Ginet, F. Michel, L. Villon, J.-P. Cristol, and C. Colette Activation of Oxidative Stress by Acute Glucose Fluctuations Compared With Sustained Chronic Hyperglycemia in Patients With Type 2 Diabetes JAMA, April 12, 2006; 295(14): 1681 - 1687. [Abstract] [Full Text] [PDF]

				E. S. Huang, M. Shook, L. Jin, M. H. Chin, and D. O. Meltzer The Impact of Patient Preferences on the Cost-Effectiveness of Intensive Glucose Control in Older Patients With New-Onset Diabetes Diabetes Care, February 1, 2006; 29(2): 259 - 264. [Abstract] [Full Text] [PDF]

				A. Bagust and P. McEwan Guidelines for Computer Modeling of Diabetes and Its Complications: Response to American Diabetes Association Consensus Panel Diabetes Care, February 1, 2005; 28(2): 500 - 500. [Full Text] [PDF]

				B. A. Young, W. J. Katon, M. Von Korff, G. E. Simon, E. H. B. Lin, P. S. Ciechanowski, T. Bush, M. Oliver, E. J. Ludman, and E. J. Boyko Racial and Ethnic Differences in Microalbuminuria Prevalence in a Diabetes Population: The Pathways Study J. Am. Soc. Nephrol., January 1, 2005; 16(1): 219 - 228. [Abstract] [Full Text] [PDF]

				American Diabetes Association Consensus Panel Guidelines for Computer Modeling of Diabetes and Its Complications Diabetes Care, September 1, 2004; 27(9): 2262 - 2265. [Full Text] [PDF]

				H. Eyre, R. Kahn, R. M. Robertson, and and the ACS/ADA/AHA Collaborative Writing Committe Preventing Cancer, Cardiovascular Disease, and Diabetes: A Common Agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association Stroke, August 1, 2004; 35(8): 1999 - 2010. [Abstract] [Full Text] [PDF]

				H. Eyre, R. Kahn, R. M. Robertson, and the ACS/ADA/AHA Collaborative Writing Committe, N. G. Clark, C. Doyle, T. Gansler, T. Glynn, Y. Hong, R. A. Smith, et al. Preventing Cancer, Cardiovascular Disease, and Diabetes: A Common Agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association CA Cancer J Clin, July 1, 2004; 54(4): 190 - 207. [Abstract] [Full Text] [PDF]

				H. Eyre, R. Kahn, and R. M. Robertson Preventing Cancer, Cardiovascular Disease, and Diabetes: A common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association Diabetes Care, July 1, 2004; 27(7): 1812 - 1824. [Abstract] [Full Text] [PDF]

				H. Eyre, R. Kahn, R. M. Robertson, the ACS/ADA/AHA Collaborative Writing Committee, ACS/ADA/AHA Collaborative Writing Committee Member, N. G. Clark, C. Doyle, Y. Hong, T. Gansler, T. Glynn, et al. Preventing Cancer, Cardiovascular Disease, and Diabetes: A Common Agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association Circulation, June 29, 2004; 109(25): 3244 - 3255. [Abstract] [Full Text] [PDF]

				T. J. Hoerger, R. Harris, K. A. Hicks, K. Donahue, S. Sorensen, and M. Engelgau Screening for Type 2 Diabetes Mellitus: A Cost-Effectiveness Analysis Ann Intern Med, May 4, 2004; 140(9): 689 - 699. [Abstract] [Full Text] [PDF]

				L. M. Pogach, S. A. Brietzke, C. L. Cowan Jr., P. Conlin, D. J. Walder, and C. T. Sawin Development of Evidence-Based Clinical Practice Guidelines for Diabetes: The Department of Veterans Affairs/Department of Defense Guidelines Initiative Diabetes Care, May 1, 2004; 27(suppl_2): B82 - B89. [Abstract] [Full Text] [PDF]

				A. Arredondo and A. Zuniga Economic Consequences of Epidemiological Changes in Diabetes in Middle-Income Countries: The Mexican case Diabetes Care, January 1, 2004; 27(1): 104 - 109. [Abstract] [Full Text] [PDF]

				D. M. Eddy and L. Schlessinger Archimedes: A trial-validated model of diabetes Diabetes Care, November 1, 2003; 26(11): 3093 - 3101. [Abstract] [Full Text] [PDF]

				R. Kahn Dealing With Complexity in Clinical Diabetes: The value of Archimedes Diabetes Care, November 1, 2003; 26(11): 3168 - 3171. [Full Text] [PDF]

				W. H. Herman Diabetes Modeling Diabetes Care, November 1, 2003; 26(11): 3182 - 3183. [Full Text] [PDF]

				M. Brandle, H. Zhou, B. R.K. Smith, D. Marriott, R. Burke, B. P. Tabaei, M. B. Brown, and W. H. Herman The Direct Medical Cost of Type 2 Diabetes Diabetes Care, August 1, 2003; 26(8): 2300 - 2304. [Abstract] [Full Text] [PDF]

				A. Bagust and S. Beale Deteriorating beta-cell function in type 2 diabetes: a long-term model QJM, April 1, 2003; 96(4): 281 - 288. [Abstract] [Full Text] [PDF]

				S. Vijan and R. A. Hayward Treatment of Hypertension in Type 2 Diabetes Mellitus: Blood Pressure Goals, Choice of Agents, and Setting Priorities in Diabetes Care Ann Intern Med, April 1, 2003; 138(7): 593 - 602. [Abstract] [Full Text] [PDF]

				S. R. Earnshaw, A. Richter, S. W. Sorensen, T. J. Hoerger, K. A. Hicks, M. Engelgau, T. Thompson, K. M. V. Narayan, D. F. Williamson, E. Gregg, et al. Optimal Allocation of Resources Across Four Interventions for Type 2 Diabetes Med Decis Making, October 1, 2002; 22(5_suppl): S80 - S91. [Abstract] [PDF]

				V. Kothari, R. J. Stevens, A. I. Adler, I. M. Stratton, S. E. Manley, H. A. Neil, and R. R. Holman UKPDS 60: Risk of Stroke in Type 2 Diabetes Estimated by the UK Prospective Diabetes Study Risk Engine Stroke, July 1, 2002; 33(7): 1776 - 1781. [Abstract] [Full Text] [PDF]

				The CDC Diabetes Cost-effectiveness Group Cost-effectiveness of Intensive Glycemic Control, Intensified Hypertension Control, and Serum Cholesterol Level Reduction for Type 2 Diabetes JAMA, May 15, 2002; 287(19): 2542 - 2551. [Abstract] [Full Text] [PDF]

				J. J. Caro, A. J. Ward, and J. A. O'Brien Lifetime Costs of Complications Resulting From Type 2 Diabetes in the U.S. Diabetes Care, March 1, 2002; 25(3): 476 - 481. [Abstract] [Full Text] [PDF]

				M. Lamotte, L. Annemans, A. Lefever, M. Nechelput, and J. Masure A Health Economic Model to Assess the Long-Term Effects and Cost-Effectiveness of Orlistat in Obese Type 2 Diabetic Patients Diabetes Care, February 1, 2002; 25(2): 303 - 308. [Abstract] [Full Text] [PDF]

				E. H. Wagner, N. Sandhu, K. M. Newton, D. K. McCulloch, S. D. Ramsey, and L. C. Grothaus Effect of Improved Glycemic Control on Health Care Costs and Utilization JAMA, January 10, 2001; 285(2): 182 - 189. [Abstract] [Full Text] [PDF]

				G. S. Meneilly and D. Tessier Diabetes in Elderly Adults J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2001; 56(1): 5M - 13. [Abstract] [Full Text]

				M. H. Chin, A. W. Su, L. Jin, and M. P. Nerney Variations in the Care of Elderly Persons With Diabetes Among Endocrinologists, General Internists, and Geriatricians J. Gerontol. A Biol. Sci. Med. Sci., October 1, 2000; 55(10): 601M - 606. [Abstract] [Full Text]

				J. C. Javitt, G. C. Brown, M. M. Brown, S. Sharma, H. D. Hoskins, Jr, S. Vijan, T. P. Hofer, and R. A. Hayward How Often Should Patients With Diabetes Be Screened for Retinopathy? JAMA, July 26, 2000; 284(4): 437 - 439. [Full Text] [PDF]

				A. Gray, M. Raikou, A. McGuire, P. Fenn, R. Stevens, C. Cull, I. Stratton, A. Adler, R. Holman, and R. Turner Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41) BMJ, May 20, 2000; 320(7246): 1373 - 1378. [Abstract] [Full Text]

				S. Vijan, T. P. Hofer, and R. A. Hayward Cost-Utility Analysis of Screening Intervals for Diabetic Retinopathy in Patients With Type 2 Diabetes Mellitus JAMA, February 16, 2000; 283(7): 889 - 896. [Abstract] [Full Text] [PDF]

				E. Goyder and L. Irwig Screening for diabetes: what are we really doing? BMJ, December 12, 1998; 317(7173): 1644 - 1646. [Full Text]

				The CDC Diabetes Cost-Effectiveness Study Group The Cost-effectiveness of Screening for Type 2 Diabetes JAMA, November 25, 1998; 280(20): 1757 - 1763. [Abstract] [Full Text] [PDF]

				M. A. Testa and D. C. Simonson Health Economic Benefits and Quality of Life During Improved Glycemic Control in Patients With Type 2 Diabetes Mellitus: A Randomized, Controlled, Double-Blind Trial JAMA, November 4, 1998; 280(17): 1490 - 1496. [Abstract] [Full Text] [PDF]

				UK Prospective Diabetes Study Group Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40 BMJ, September 12, 1998; 317(7160): 720 - 726. [Abstract] [Full Text]

				R. J. Rubin, K. A. Dietrich, and A. D. Hawk Clinical and Economic Impact of Implementing a Comprehensive Diabetes Management Program in Managed Care J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2635 - 2642. [Abstract] [Full Text]